Home | Welcome to Contract Pharma   
Last Updated Friday, May 24 2013
Print RSS Feed

Breaking News

Related Searches: Financial Reports •
Financial Report: Hospira 1Q09

April 28, 2009
Global Specialty Injectables revenue was down 7.5% to 429.7 million, with Europe, Middle East & Africa sales down 26% to $57.6 million and the Americas down 2% to $333.1 million.  Read More »
Eurand N.V.

April 28, 2009
Robert Becker, M.D. has been appointed to the newly created position of chief research officer of Eurand SpA, effective April 20th.  Read More »
Patheon Signs OROS Agreements

April 27, 2009
Patheon has signed agreements to commercialize two controlled release products utilizing OROS technology from its Cincinnati facility.   Read More »
Novozymes Biopharma Builds cGMP bHA Facility

April 27, 2009
Novozymes Biopharma has begun construction of a new cGMP facility at its existing site in Tianjin, China, enabling the company to produce Bacillus-based Hyaluronic Acid (bHA), HyaCare, for the bio-medical and pharmaceutical industries.  Read More »
Wyeth's Conbriza Gains EU Approval

April 27, 2009
Wyeth received marketing authorization from the European Commission for Conbriza (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.   Read More »
Financial Report: Amgen 1Q

April 24, 2009
Total product sales were down 8% to $3.2 billion, partly reflecting the negative impact of foreign exchange. Sales in the U.S. were $2.5 billion (-10%).  Read More »
Roche, SLCG To Investigate new Tarceva Strategy

April 24, 2009
Roche and the Spanish Lung Cancer Group (SLCG) will collaborate on the first Phase III trial to investigate Tarceva in lung cancer patients with genetic mutations in their epidermal growth factor receptor (EGFR).  Read More »
Almac, PHT Form Clinical Trial Quality Alliance

April 24, 2009
Almac Clinical Technologies and PHT Corp. have entered an alliance to improve clinical trial productivity through various education initiatives and data integration efforts aimed at reducing trial site problems and improving data collection and reporting.  Read More »
Financial Report: Gilead 1Q

April 23, 2009
Product sales were up 27% to a record $1.5 billion driven by the antiviral franchise, with sales up 28% to $1.3 billion.  Read More »
Financial Report: Elan 1Q

April 23, 2009
Biopharmaceutical business revenue was up 28% driven by Tysabri sales, offsetting reduced sales of Azactam and Maxipime.   Read More »
Sandoz Canada's HGH Biosimilar Approved

April 23, 2009
Sandoz Canada received market authorization for Omnitrope in Canada. Omnitrope is the first biosimilar of a previously approved recombinant drug to be approved by Health Canada under Subsequent Entry Biologic (SEB).  Read More »
Financial Report: GlaxoSmithKline 1Q

April 22, 2009
Pharmaceutical product sales in the quarter were $8.1 billion (-15%). Seretide/Advair sales were $1.7 billion (-11%).   Read More »
Avastin Study Misses Endpoint In Early-Stage Colon Cancer

April 22, 2009
Genentech's Phase III study of Avastin (bevacizumab) plus chemotherapy in patients with early-stage colon cancer (NSABP C-08) did not meet its primary endpoint of reducing the risk of cancer returning.  Read More »
Financial Report: PPD 1Q

April 22, 2009
Development segment revenue was $335.4 million (-7%). Discovery sciences segment revenue was $5.7 million (-64%).  Read More »
Financial Report: Genzyme 1Q

April 22, 2009
Myozyme sales were flat at $67.4 million. In February, the company received EU approval of Myozyme produced at the 4000 L scale.  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: